Mesoporous silica (MCM-41) can encapsulate drugs, prevent drug recrystallization, and improve dispersibility. MCM-41, a carrier with many advantages, can be applied for febuxostat solubilzation. The purpose of this study is to develop a febuxostat solid dispersion (SD) containing MCM-41 and Kollidon® (K12) to improve the dissolution rate and ensure stability. The SD preparation method was a solvent evaporation. The final formulation (SD1, febuxostat :MCM-41 : Kollidon®(K12)=1:5:2 [w/w]) was successfully developed. The melting point and crystallinity of febuxostat in the SD1 formulation have changed, and drug-excipient interactions were also confirmed. Based on these results, it is believed that the dissolution rate was improved by 6.2- (pH 1.2 media), 2.1- (distilled water), and 1.1-fold (pH 6.8 buffer) compared to the commercial product. In conclusion, the febuxostat-SD through a ternary system was successfully developed, which is believed to be due to the physicochemical changes in the SD1 formulation.
서 론(Introduction)
방 법(Methods)
결과 및 고찰(Results and Discussion)
결 론(Conclusion)
감사의말씀(Acknowledgment)
Conflict of Interest
References